BIOXYTRAN
BioXyTran operates as a biopharmaceutical company whose mission is to develop anti-necrosis drugs that treat a variety of medical conditions resulting from stroke and Ischemia. The company was founded in 2008 and is headquartrered in
BIOXYTRAN
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2008-01-01
Address:
Newton, Massachusetts, United States
Country:
United States
Website Url:
http://www.bioxytraninc.com
Total Employee:
1+
Status:
Active
Contact:
617-454-1199
Email Addresses:
[email protected]
Total Funding:
600 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Apache
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.bioxytraninc.com Semrush global rank: 5.89 M Semrush visits lastest month: 1.4 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "BioXyTran"
Company
[email protected]. Follow us on Twitter. Follow us on Facebook. Follow us on Instagram. Follow us on LinkedIn. All statements and expressions are the sole opinion of the editor and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any ...See details»
Anti-Necrosis Drugs - BXT-25 & BXT-252 | BioXyTran
Bioxytran, Inc. is a biopharmaceutical company whose mission is to develop anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia.The company focuses on the development and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke.See details»
BioXyTran - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 617-454-1199 BioXyTran operates as a biopharmaceutical company whose mission is to develop anti-necrosis drugs that treat a variety of medical conditions resulting from stroke and Ischemia.See details»
Bioxytran, Inc. - LinkedIn
Bioxytran, Inc. Pharmaceutical Manufacturing NEEDHAM , Massachusetts 338 followers Bioxytran is a company focused on developing treatments for stroke and Ischemia.See details»
BioXyTran, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
More information can be found at www.bioxytraninc.com Investor RelationsMichael [email protected] Forward-Looking Statements This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release.See details»
Bioxytran Expands Institutional Investor Base with an additional ...
Jun 12, 2023 The funding is sufficient to reach the next milestone of a submission of a Phase 3 regulatory trial in India for mild to moderate COVID-19. Bioxytran’s Clinical Research Organization (CRO) has ...See details»
Bioxytran Expands Institutional Investor Base with an
Dec 6, 2023 More information can be found at www.bioxytraninc.com About TRITON FUNDS As the nation's premier student-managed fund, TRITON FUNDS empowers students with real-world experience in Venture Capital ...See details»
Management, Board of Directors, and Advisory Board | BioxyTran
He currently works with that organization to design, supervise, and evaluate reproductive and developmental toxicity, neurotoxicity, inhalation, and photobiology studies. Dr. Hoberman holds a PhD in toxicology from Pacific Western University, an MS in interdisciplinary toxicology from the University of Arkansas, and a BS in biology from Drexel University.See details»
Bioxytran Announces FDA Clearance of its IND Application for …
Aug 24, 2023 First Antiviral Drug in Glycovirology BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral ...See details»
Bioxytran Announces Broad Spectrum Antiviral Activity
Sep 14, 2023 More information can be found at www.bioxytraninc.com. Investor Relations. Michael Sheikh 509-991-0245 [email protected]. Forward-Looking Statements.See details»
Bioxytran Receives Approval to Initiate Trials with - GlobeNewswire
Feb 6, 2023 [email protected] Forward-Looking Statements This press release includes forward-looking statements as defined under federal law, including those related to the performance of ...See details»
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
Feb 6, 2023 BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases announced the receipt of an Investigational New Drug (IND) authorization letter from India’s Central Drugs Standard Control Organization (CDSCO) to evaluate the safety, tolerability, …See details»
Bioxytran Expands Institutional Investor Base with an ... - Nasdaq
Jun 12, 2023 Bioxytran’s Clinical Research Organization (CRO) has indicated that dosing in the 40-patient trial is expected to commence within the month now that the funding is in place.See details»
Bioxytran Announces Positive Phase 2 Trial Results were Featured …
Mar 29, 2023 Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most symptoms by day 7 Galectin antagonist acts as an entry inhibitor for use in ...See details»
Resources - | BioXyTran
Today, there are more than 640 primary stroke centers certified by The Joint Commission (a private non-profit organization that provides certification programs for health care organizations, including hospitals) operating in 49 states and the District of Columbia, said Jean Range, The Joint Commission executive director of Disease-Specific Care Certification.See details»
Invest in BioXyTran - Biopharmaceuticals | BioXyTran
[email protected]. Follow us on Twitter. Follow us on Facebook. Follow us on Instagram. Follow us on LinkedIn. All statements and expressions are the sole opinion of the editor and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any ...See details»
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization
Feb 21, 2024 More information can be found at www.bioxytraninc.com. Investor Relations Michael Sheikh 509-991-0245 [email protected]. Forward-Looking Statements.See details»
Bioxytran Receives Approval to Optimize Dosage in COVID-19
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and ...See details»
Press Releases - New Developments in BioXyTran
BOSTON, MASSACHUSETTS, December 8, 2022: BioxyTran Inc. announces the receipt of an Investigational New Drug (IND) authorization letter from India’s Central Drugs Standard Control Organization (CDSCO) to optimize dosage in Covid-19 patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.See details»